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Background: NKX2-5, GATA4 and HAND1 are essential for heart development, however, little is known regarding
their epigenetic regulation in the pathogenesis of tetralogy of fallot (TOF).
Methods: Methylation levels were measured in three regions of NKX2-5 (M1: -1596 bp ~ −1374 bp, M2: -159
bp ~ 217 bp and M3: 1058 bp ~ 1524 bp), one region of GATA4 (M: -392 bp ~ 107 bp) and three regions of HAND1
(M1: -887 bp ~ −414 bp, M2: -436 bp ~ 2 bp and M3: 37 bp ~ 398 bp) using the Sequenom MassARRAY platform.
QRT-PCR was used to analyze NKX2-5 and HAND1 mRNA levels in the right ventricular myocardium of TOF patients.
Results: TOF patients had a significantly higher NKX2-5_M3 median methylation level than controls (41.65% vs.
22.18%; p = 0.0074; interquartile range [IQR]: 30.46%–53.35%, N = 30 and 20.07%–24.31%, N = 5; respectively). The
HAND1_M1 median methylation level was also significantly higher in TOF patients than controls (30.05% vs. 17.54%;
p = 0.0054; IQR: 20.77%–40.89%, N = 30 and IQR: 14.69%–20.64%; N = 6; respectively). The methylation statuses of
NKX2-5_M1, NKX2-5_M2, GATA4_M, HAND1_M2 or HAND1_M3 were not significantly different in TOF patients
compared to controls. The methylation values for NKX2-5_M3 were negatively correlated with mRNA levels
(r = − 0.463, p = 0.010, N = 30) and there was a significant association between HAND1_M1 methylation status and
mRNA levels (r = − 0.524, p = 0.003, N = 30) in TOF patients.
Conclusions: Aberrant methylation statuses of the NKX2-5 gene body and HAND1 promoter regions are associated
with the regulation of gene transcription in TOF patients and may play an important role in the pathogenesis of
TOF.
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Tetralogy of fallot (TOF) is a cyanotic, congenital car-
diac defect that is caused by improper development of
the right side of the heart [1]. TOF occurs in 3.6 of every
10,000 live births and accounts for 10% of all congenital
heart defects (CHD) [2]. TOF is a complex heart condi-
tion that is characterized by a malalignment of the conal
septum, which leads to a rightward deviation of the
aorta and results in a large ventricular septal defect,
along with varying degrees of right ventricular outflow* Correspondence: duanma@yahoo.cn; gyhuang@shmu.edu.cn
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reproduction in any medium, provided the ortract narrowing [3]. Although treatment has advanced
dramatically over the past few decades, the exact eti-
ology of TOF is unknown. There are still some TOF pa-
tients (0.5% to 6%) that suffer sudden cardiac death,
despite undergoing treatment [4]. Genetic studies have
identified numerous genes that are responsible for inher-
ited and sporadic congenital heart diseases. Most of
these, including NKX2-5, GATA4 and HAND1, encode
transcription factors that regulate specific phases of
heart development [5]. Mutations in NKX2-5, the gene
that regulates cardiac development, have been identified
in patients with TOF [6,7]. GATA4 is thought to regulate
cardiac gene expression and physically interacts with
NKX2-5. Mutations in GATA4 may lead to defective
interactions with NKX2-5, leading to congenital heart dis-
eases [8]. HAND1 is a basic, helix-loop-helix transcriptionLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Mutations in this gene have been reported in patients with
ventricular septal defect (VSD) [9,10]. Mutations of single
genes, including JAG1 [11,12], JAG5 [13], ZFPM2/FOG2
[14] and TBX20 [15], have reportedly been found in TOF
patients. However, single gene mutations or absences have
only been found in a small percentage of patients and are
not considered to be the main cause of TOF [16]. Further-
more, reports of somatic gene mutations in formalin-fixed,
paraffin embedded cardiac tissue have not been confirmed
in subsequent studies with fresh, frozen cardiac tissue,
which consistently demonstrate an absence of somatic gene
mutations. In fixed cardiac tissue, formalin can cause ran-
dom base damage, affecting polymerase chain reaction
(PCR) fidelity [17], thereby increasing the risk for poor data
quality. Therefore, somatic mutation data obtained in fresh,
frozen cardiac tissue may be more accurate and the inci-
dence of single gene mutations is likely lower than is indi-
cated from studies of fixed cardiac tissue. Interestingly,
most of the genes above have shown significant changes in
expression in the cardiovascular tissue of TOF patients
[18]. Epidemiological data has also indicated that environ-
mental influences may play a role in the etiology of TOF
[19]. Epigenetic influences must be considered in order to
understand the mechanisms that lead gene-environment
interactions to cause disease [20]. Currently, the most
widely studied epigenetic modification in humans is DNA
methylation, which occurs almost exclusively in the context
of CpG dinucleotides that control the transcriptional activ-
ity of genes [21]. Aberrant DNA methylation can result in
silencing gene expression and functional inactivation [22].
This has been demonstrated in various human diseases,
such as glioblastoma [23], chronic lymphocytic leukemia
(CLL) [24] and invasive cervical cancer (ICC) [25]. Although
mutations in NKX2-5, GATA4 and HAND1 have been
found in patients with TOF, little is known about changes
in these genes due to DNA methylation.
The goal of the present study was to explore DNA
methylation changes in NKX2-5, GATA4 and HAND1
and to examine the epigenetic regulation of these genes
in the right ventricular myocardium of TOF patients.
These results may offer a deeper understanding of the
etiology of this disease and provide important clues for
the development of new treatments for TOF.
Methods
Patients and controls
TOF cases were obtained from the Children’s Hospital
of Fudan University, Shanghai, China. Cardiovascular
diagnosis was done using echocardiography. All TOF
subjects were assessed for 22q11.2 deletions; only TOF
patients without the 22q11 deletion syndrome were in-
cluded. A total of 30 patients with TOF were studied,
including 20 (66.7%) males and 10 (33.3%) females,ranging in age from 0.25 to 4.0 years (mean ± SD: 1.13 ±
0.85 years).
The control group was comprised of autopsy speci-
mens from normal subjects that had died as a result of
accidents. Specimens were collected at the Forensic
Medicine Department of Fudan University, Shanghai,
China. Control samples were chosen in which the time
interval between death and autopsy was as short as pos-
sible so that any delays before autopsy would be taken
into account. The post mortem interval (PMI) for the
control samples was no more than 24 hours. Specimens
from six age-matched normal controls were obtained,
including 4 (66.7%) males and 2 (33.3%) females, ranging
in age from 0.5 to 4.5 years (mean ± SD: 1.73 ±
1.44 years). Characteristics of the study subjects are
summarized in Additional file 1: Table S1.
All tissue samples were obtained from the right ven-
tricular myocardium tissues immediately after surgical
resection or autopsy and stored in RNAlater® (AMBION,
Inc., Austin, TX, U.S.) until use to exclude any tissue
heterogeneity that may affect methylation results.
This study was approved by the local ethics committee
of Fudan University. Written informed consent was ob-
tained from the parents or relatives of all study subjects.
DNA extraction and sodium bisulfite conversion
A QIA amp DNA Mini Kit (Qiagen, Hilden, Germany) was
used to extract genomic DNA, according to the manufac-
turer’s instructions, from the heart tissue samples of TOF
patients and controls. The concentration and purity of gen-
omic DNA were measured via absorbance at 260 and
280 nm using a NanoDropTM 1000 Spectrophotometer
(Thermo Scientific, Wilmington, U.S.). Sodium bisulfite
modification of genomic DNA was done, strictly according
to manufacturer’s instructions, using an EZ DNA Methyla-
tion Kit™ (Zymo Research, Orange, CA, U.S.). Sequencing
results confirmed that more than 99.0% of cytosine residues
were converted. The bisulfite converted DNA was re-
suspended in 10 μl elution buffer and stored at −80°C until
the samples were ready for analysis.
Quantitative MassARRAY analysis of gene methylation
status
Quantitative methylation analysis for NKX2-5, GATA4
and HAND1 was performed based on base-specific
cleavage and MALDI-TOF mass spectrometry, as rec-
ommended by the manufacturer, using the MassArray
EpiTyper (Sequenom, San Diego, CA, U.S.). The Seque-
nom groups have demonstrated the robustness of this
approach for quantifying methylated and unmethylated
DNA [26]. The primers used in this study were designed
using http://epidesigner.com (Additional file 1: Table S2.).
For each reverse primer, an additional T7 promoter tag
was added for in vivo transcription and a 10-mer tag was
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temperature differences. All experiments were performed
as described previously [27].
The accuracy of the methylation analysis results from the
MALDI-TOF MassARRAY (Sequenom) were confirmed by
pyrosequencing and bisulfite sequencing PCR (BSP) [28].
RNA extraction and quantitative RT-PCR
Total RNA was extracted from heart tissue samples using
Trizol Reagent (Invitrogen, CA, U.S.), according to the man-
ufacturer's instructions. RNA was reverse-transcribed using
a PrimeScript RT reagent Kit with gDNA Eraser (Perfect
Real Time, TaKaRa, Otsu, Shiga, Japan) and the integrity of
synthesized cDNA was confirmed using glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) as the endogenous
control. Quantitative RT-PCR was performed in a 7900 real-
time PCR system using SYBR Premix Ex Taq GC (Perfect
Real Time, TaKaRa) using a 10 μl reaction volume, contain-
ing 5 μl SYBR Premix Ex Taq GC, 0.2 μM of each primer,
0.2 μ ROX1 Reference Dye and 100 ng cDNA. Reactions
were performed in triplicate and analyzed using an ABI
7900 Sequence Detection System (Applied Biosystems).
Relative expression levels were calculated according to the
standard 2-ΔΔCt method using beta-2 microglobulin (B2M)
and the GAPDH gene as the endogenous control for
normalization. Primer sequences used in the QRT-PCR
analysis are listed in Additional file 1: Table S3.
Statistical analysis
Data were analyzed using GraphPad Prism (version 5.0;
GraphPad Software Inc., San Diego, CA, U.S.) and SPSSFigure 1 Median methylation levels for NKX2-5 in TOF patients and c
and CpG island in the NKX2-5 gene; (B) NKX2-5_M1 median methylation le
methylation level. All of the values represent the median with the interqua
thick bars, CpG islands; M,MassARRAY amplicon; The region between arrow
(Mann–Whitney test).(version 13.0; SPSS Inc., Chicago, IL, U.S.). The Mann–
Whitney test was performed to evaluate the significance
of any differences between the TOF and control groups.
Spearman correlation analysis was performed to evaluate
the correlations between the methylation statuses and
mRNA levels of the NKX2-5 and HAND1 genes. All stat-
istical analysis was 2-sided and P < 0.05 was considered
statistically significant.
Results
Methylation levels for NKX2-5, GATA4 and HAND1 genes
in TOF patients and controls
The methylation statuses of NKX2-5, GATA4 and HAND1
genes were analyzed using the Sequenom MassARRAY
platform. Three amplicons, including three regions, in
NKX2-5 (M1: -1596 bp ~ −1374 bp, M2: -159 bp ~ 217 bp
and M3: 1058 bp ~ 1524 bp, Figure 1A), one amplicon,
including one region, in GATA4 (M: -392 bp ~ 107 bp,
Figure 2A) and three amplicons, including three regions, in
HAND1 (M1: -887 bp ~ −414 bp, M2: -436 bp ~ 62 bp and
M3: 37 bp ~ 398 bp, Figure 3A) were analyzed in specimens
from 10 patients with TOF and 6 age matched controls.
Prior to analysis, strict quality control was performed to re-
move potentially unreliable measurements. The CpG units
that failed to produce data from more than 30% of samples
(unreliable CpG units) and samples missing more than 30%
of the data points (unreliable samples) were discarded [29].
The methylation level of the NKX2-5_M3 amplicon
was significantly higher, with a median of 34.12% (IQR:
32.03%–48.86%, N =10) in TOF patients, compared to
a median of 22.18% in controls (IQR: 20.07%–24.31%;ontrols. (A) The schematic represents the distribution of the CpG site
vel; (C) NKX2-5_M2 median methylation level; (D) NKX2-5_M3 median
rtile range. TSS, Transcription Start Sites; red vertical line, CpG sites; red
s, target amplicon. *p < 0.05, **p < 0.01, ***p < 0.001
Figure 2 Median methylation levels for GATA4 in TOF patients and controls. (A) The schematic represents the distribution of the CpG site and
CpG island in the GATA4 gene; (B) The sequence shown represents a 500 base pair fragment (positions −392 – 107) in the 5′-UTR of GATA4; (C) GATA4_M
median methylation level. All of the values represent the median with the interquartile range. TSS, Transcription Start Sites; red vertical line, CpG sites; red
thick bars, CpG islands; M,MassARRAY amplicon; The region between arrows, target amplicon. *p< 0.05, **p< 0.01, ***p< 0.001 (Mann–Whitney test).
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cluded, Figure 1D). Methylation levels in the NKX2-
5_M1 and NKX2-5_M2 amplicons were not significantly
different between the TOF and control subjects (Figure 1B
and Figure 1C).Figure 3 Median methylation levels for HAND1 in TOF patients and co
and CpG island in the HAND1 gene; (B) HAND1_M1 median methylation le
methylation level. All of the values represent the median with the interqua
thick bars, CpG islands; M,MassARRAY amplicon; The region between arrow
(Mann–Whitney test).There was no significant difference in the methylation
level for GATA4 _M when comparing the TOF and con-
trol subjects (Figure 2C). The methylation level of
HAND1_M1 was significantly higher in TOF subjects,
with a median of 30.77% (IQR: 21.59%–51.65%, N = 10)ntrols. (A) The schematic represents the distribution of the CpG site
vel; (C) HAND1_M2 median methylation level; (D) HAND1_M3 median
rtile range. TSS, Transcription Start Sites; red vertical line, CpG sites; red
, target amplicon. *p < 0.05, **p < 0.01, ***p < 0.001
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N = 6, Figure 3B) in the control group. No signifi-
cant difference was observed in the methylation levels
for HAND1_M2 and HAND1_M3 when comparing
TOF and control subjects (Figure 3C and Figure 3D,
respectively).
Pyrosequence was used to determine the methylation
status of NKX2-5_P in 2 TOF patients and in 1 control
and BSP was used to measure the methylation level of
GATA4_B in 2 TOF patients and in 2 controls to con-
firm the accuracy of the MALDI-TOF MassARRAY
(Sequenom) methylation analysis. NKX2-5_P and
GATA4_B overlapped with NKX2-5_M2 and GATA4_M
(Figures 4A and 5A, respectively). Primer sequences
used are listed in Additional file 1: Table S4.
As shown in Figure 4, the methylation value for
NKX2-5_P was less than 10%. This result was similar to
that found using the MassARRAY methylation analysis
for NKX2-5_M2. Methylation analysis results from BSP
for GATA4_B were also consistent with the MassARRAY
methylation analysis results for GATA4_M (Figure 5).
These data confirmed the accuracy of methylationFigure 4 Pyrosequencing results for NKX2-5. (A) A schematic of the gen
methylation is depicted by the orange bars with the numbers and sequen
TSS; (B) T1 sample pyrosequencing results; (C) T2 sample pyrosequencing
N, normal samples; TSS, Transcription Start Sites.analysis results from the MALDI-TOF MassARRAY
(Sequenom).
Validation of different methylation levels for NKX2-5_M3
and HAND1_M1
The Sequenom MassARRAY platform was used to valid-
ate and compare the different methylation levels of
NKX2-5_M3 and HAND1_M1 in 20 patients with TOF
and 6 age matched controls. As shown in Figure 6A, the
methylation level of NKX2-5_M3 was significantly
higher in patients with TOF, with a median value of
45.06% (IQR: 25.93%–54.36%, N = 20) compared to
22.18% (IQR: 20.07%–24.31%, p = 0.0383,N = 5, one
male, aged 1.9 years, not included) in controls. Further-
more, patients with TOF also had significantly higher
methylation levels for HAND1_M1, with a median value
of 30.01% (IQR: 19.82%–39.11%, N = 20) compared to
17.54% (IQR: 14.69%–20.64%; N = 6, p = 0.0137, Figure 6B)
in controls.
The NKX2-5_M3 and HAND1_M1 methylation levels
in the 20 TOF patients and the initial 10 TOF subjects
were combined and compared to those of the controlomic structure of the NKX2-5 gene. The region analyzed for DNA
ces showing the location of pyrosequence production with respect to
results; (D) N1 sample pyrosequencing results; T, TOF samples;
Figure 5 Bisulfite sequencing PCR (BSP) results for GATA4. (A) A schematic represents the distribution of the CpG site in the GATA4 gene and
the analyzed sequence represents a 413 base pair fragment (positions −296–116) in the promoter region of GATA4 gene; (B) BSP sequencing
results, N1 and N2 represent the normal control, T1 and T2 represent the TOF subjects; (C) Methylation level for GATA4_M.
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level was found in TOF patients, with a median value of
41.65% (IQR: 30.46%–53.35%, N = 30) compared to
22.18% (IQR: 20.07%–24.31%, N = 5) in controls (p =
0.0074, Figure 6C). The HAND1_M1 methylation level
was also significantly higher in TOF patients, with a me-
dian value of 30.05% (IQR: 20.77%–40.89%, N = 30)
compared to 17.54% (IQR: 14.69%–20.64%, N = 6) in
controls (p = 0.0054, Figure 6D).
Expression levels of NKX2-5 and HAND1 mRNA in patients
with TOF and controls
The mRNA expression levels of the NKX2-5 and
HAND1 genes were determined by QRT-PCR in 30 TOF
patients and 6 controls. The normalized Ct mean (ΔCt),
ΔΔCt and RQ (2-ΔΔCt) values for NKX2-5 and HAND1
genes in each samples are listed in Additional file 1:
Table S5. The RQ value (2-ΔΔCt) for control 1 was set as
1 and used for normalization for all samples.As shown in Table 1, NKX2-5 and HAND1 mRNA
relative expression levels (RQ values) were significantly
lower in patients with TOF compared with controls
(p < 0.05).
Association between the methylation statuses and mRNA
levels of NKX2-5 and HAND1
A correlation analysis was done, in TOF patients, to
identify any relationship between NKX2-5 and HAND1
methylation status and their respective mRNA levels.
As shown in Figure 7A, a significant association was
observed between the methylation status and mRNA
level of NKX2-5_M3 (r = −0.463, p = 0.010, N = 30).
Similarly, there was a significant association between the
methylation status and mRNA level of the HAND1 gene
(r = −0.524, p = 0.003, N = 30, Figure. 7B).
The association between NKX2-5 and HAND1 methy-
lation status and their respective mRNA levels was
also analyzed without the initial 10 TOF subjects.
Figure 6 Comparison of median methylation level for NKX2-5_M3 and HAND1_M1 in the control and TOF subjects. (A) Median
methylation level for NKX2-5_M3 of 5 control and 20 TOF subjects; (B) Median methylation level for HAND1_M1 of 6 control and 20 TOF subjects;
(C) Median methylation level for NKX2-5_M3 of 5 control and 30 TOF subjects; (D) Median methylation level for HAND1_M1 of 6 control and 30
TOF subjects. *p <0.05, **p < 0.01, ***p < 0.001 (Mann–Whitney test).
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between the NKX2-5_M3 methylation status and mRNA
level (r = −0.468, p = 0.038, N = 20, Figure 7C). A signifi-
cant association was also observed between the methyla-
tion status and mRNA level of HAND1 (r = −0.478, p =
0.033, N = 20, Figure 7D).
Discussion
Epigenetic control mechanisms play key roles in the
regulation of tissue homeostasis and disease develop-
ment. This includes DNA methylation, histone modifica-
tion, the regulation of mRNA stability, translation by
non-coding RNAs and differential RNA splicing [30].Table 1 Relative mRNA expression levels of NKX2-5 and HAND
Gene Control (RQ value (2-ΔΔCt) a: mean ± SD,n = 6)
NKX2-5 9.76 ± 7.39c
HAND1 7.55 ± 5.62
a The RQ values (2-ΔΔCt) for control 1 was set as 1 and used for normalization for all
of addition and subtraction. One male, aged 1.9 years, was not included.DNA methylation constitutes an important epigenetic
regulation mechanism in many eukaryotes and has been
extensively studied [31]. In a previous study, decreased
LINE-1 methylation levels were found in the cardiac tis-
sue of TOF patients. The lower LINE-1 methylation
level may be associated with increased TOF risk [27]
and could serve as an indicator of global DNA methyla-
tion [32]. In the current study, we initially performed
quantitative methylation analysis of NKX2-5, GATA4
and HAND1 genes in the right ventricular myocardium
tissues of 10 TOF patients and 6 age matched control
subjects using the Sequenom MassARRAY platform and
found a significant difference in the methylation levels of1 in samples from controls and patients with TOF
TOF (RQ value (2-ΔΔCt): mean ± SD, n = 30) P valueb
1.48 ± 3.45 0.0028
1.20 ± 0.41 0.0032
samples; b Mann–Whitney test was performed; c “±” represents the meaning
Figure 7 Association of methylation status and mRNA levels for NKX2-5_M3 and HAND1_M1 in patients with TOF. (A) Association of
methylation status and mRNA levels for NKX2-5_M3 in 30 patients with TOF; (B) Association of methylation status and mRNA levels for
HAND1_M1 in 30 patients with TOF; (C) Association of methylation status and mRNA levels for NKX2-5_M3 in 20 patients with TOF;
(D) Association of methylation status and mRNA levels for HAND1_M1 in 20 patients with TOF. RQ values represent relative mRNA expression
levels for NKX2-5 and HAND1 genes; the RQ value (2-ΔΔCt) for control 1 was set as 1 and used for normalization for all samples. *p < 0.05,
**p < 0.01, ***p < 0.001 (Spearman).
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pared with controls (p < 0.05). The methylation values
for NKX2-5_M3 and HAND1_M1 were then validated in
a larger cohort TOF subjects. The difference in methyla-
tion levels for NKX2-5_M3 and HAND1_M1 were com-
pared, between TOF patients and controls, in two
independent cohorts. A significant difference was ob-
served in the methylation status of NKX2-5_M3 when
comparing the 20 TOF patients to the 6 controls (p =
0.0383). The methylation levels for the promoter region
of the HAND1 gene (HAND1_M1) were also signifi-
cantly different between the 20 TOF patients and the 6
controls (p = 0.0137). Interestingly, the significantdifference in the methylation levels for NKX2-5_M3
and HAND1_M1 increased when comparing the 30
TOF cases to the 6 controls (p = 0.0074, p = 0.0054,
respectively).
The MassARRAY EpiTYPER® for quantitative analysis
of DNA methylation combines base-specific enzymatic
cleavage with MALDI-TOF mass spectrometry. This
combination provides a highly accurate, sensitive and
high-throughput method for the quantitative analysis of
DNA methylation. The EpiTYPER software provides
convenient solutions for data analysis and export, how-
ever,the Sequenom EpiTYPER has a 5% technical error
rate [33]. Although the robustness of this approach for
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results has been demonstrated, we used two alternate
methods,pyrosequence and BSP,to test the methylation
analysis results of NKX2-5 and GATA4. No apparent differ-
ences were detected among these methods. This data sup-
ports the accuracy of the Sequenom MassARRAY
methylation analysis results in our study.
Increasing evidence suggests that single gene muta-
tions are present in a broad spectrum of genes involved
in cardiac structure and function. Factors, such as
NKX2-5, GATA4 and HAND1, are among the earliest
transcription factors expressed in the developing heart
and are crucial in the activation of cardiac-specific genes
[34]. Wang et al. sequenced all exons and their boundar-
ies in the NKX2-5, GATA4 and HAND1 genes from
non-syndromic TOF children and controls and found no
evidence that somatic mutations in NKX2-5, GATA4 and
HAND1 play a role in the pathogenesis of TOF [35]. Al-
though mutations in NKX2-5, GATA4 and HAND1 have
been observed in patients with TOF, they are present
only in a small percentage of TOF cases and cannot be
considered to be the main cause of TOF. Based on these
findings, we hypothesized that the aberrant DNA methy-
lation modifies these genes and likely contributes to the
development of TOF. In the present study, no significant
difference in GATA4 methylation levels were observed
between TOF patients and controls, thus the methyla-
tion status of GATA4 likely has no influence on its gene
expression. Furthermore, we found that mRNA levels of
the NKX2-5 and HAND1 genes were significantly lower
in TOF patients compared to controls (p < 0.05). We
also found significant negative correlations between
methylation status and mRNA level for NKX2-5 and
HAND1 in the 30 TOF cases (Figure 7A and B). Inter-
estingly, the associations between methylation status and
mRNA level for NKX2-5 and HAND1 were confirmed in
the 20 TOF cases without including the initial 10 TOF
subjects (Figure 7C and D). This demonstrates a consist-
ent, significant association via two independent compari-
sons. These findings indicate that changes in the
methylation levels for NKX2-5 and HAND1 may influ-
ence gene expression and contribute to the development
of TOF.
One limitation of this study was that we were unable
to obtain enough complete age-matched samples from
TOF patients and healthy controls due to the difficulty
of obtaining cardiac tissue samples. Further studies with
larger number of subjects or samples are warranted in
order to confirm our findings that aberrant methylation
contributes to TOF development. Moreover, based only
on the current results from clinical samples, we cannot
ascertain whether the noted methylation changes oc-
curred after the heart was already formed or after the
heart defect already existed. Thus, we cannot determinewhether these changes are reflective of disease physi-
ology or related to disease etiology. Related research will
be conducted using cell lines or animal models in future
studies.
Conclusion
In the present study, we examined the methylation status
of NKX2-5, GATA4 and HAND1 and found significant
changes in the methylation levels in the NKX2-5 gene body
and the HAND1 gene promoter region. In addition, the ab-
errant methylation status of NKX2-5 and HAND1 was
negatively correlated with their corresponding mRNA ex-
pression, indicating that the DNA methylation changes in
these two genes contribute to transcription regulation in
TOF patients and may play important roles in the patho-
genesis of TOF. These findings may provide important
clues for the development of novel treatments for TOF and
provide a more thorough understanding of the etiology of
congenital heart disease.
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